首页> 美国卫生研究院文献>ACS Medicinal Chemistry Letters >TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT
【2h】

TSPO 18 kDa (PBR) Targeted Photosensitizers for Cancer Imaging (PET) and PDT

机译:用于癌症成像(PET)和PDT的TSPO 18 kDa(PBR)靶向光敏剂

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Translocator protein (TSPO) 18 kDa overexpression has been observed in a large variety of human cancers, especially breast cancers. PK 11195, an isoquinoline analogue, is one of the ligands of highest TSPO binding affinity. Due to the long biological half life of our photosensitizers, there is a need to label them with a long lived radioisotope, for example I-124. Our objectives are to find translocator protein targeted photosensitizers for both tumor imaging (PET) and photodynamic therapy (PDT). I-PK 11195 is conjugated with the tumor avid photosensitizer HPPH. We find that those two tumor avid components complement each other and make the conjugate molecule even more tumor avid; compared to the photosensitizer itself, the conjugate is found to show improved PDT efficacy. It is concluded that I-PK 11195 can be a good vehicle to deliver radionuclide and photosensitizer to TSPO overexpressed tumor regions. Such conjugates could be useful for both tumor imaging (PET) and PDT.
机译:在多种人类癌症,尤其是乳腺癌中,已经观察到18kDa的Translocator蛋白(TSPO)过表达。 PK 11195是一种异喹啉类似物,是TSPO结合亲和力最高的配体之一。由于我们的光敏剂具有较长的生物半衰期,因此需要用寿命长的放射性同位素(例如I-124)标记它们。我们的目标是找到用于肿瘤成像(PET)和光动力疗法(PDT)的易位蛋白靶向光敏剂。 I-PK 11195与肿瘤狂热光敏剂HPPH缀合。我们发现这两个肿瘤狂热成分彼此互补,并使缀合物分子更加具有肿瘤狂热性。与光敏剂本身相比,发现缀合物显示出改善的PDT功效。结论是,I-PK 11195可能是将放射性核素和光敏剂传递到TSPO过表达的肿瘤区域的良好载体。这样的结合物可用于肿瘤成像(PET)和PDT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号